ReviewCureus2025
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease.Biomolecules · 2026Review
- Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with type 2 diabetes mellitus (T2DM), contributing to increased liver-related complications and cardiovascular risk. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as potential treatments offering benefits for both metabolic and liver-related outcomes. This systematic review evaluated the efficacy of SGLT2 inhibitors in improving hepatic steatosis, liver enzymes, glycemic control, and liver histology in patients with T2DM and NAFLD. The review was conducted using a structured methodology, including systematic database searches and risk of bias assessments. Included randomized controlled trials (RCTs) investigated various SGLT2 inhibitors, such as dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin. Most studies showed significant reductions in liver fat content, improvements in serum liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT)), and favorable effects on blood pressure, triglycerides, and body composition. Glycemic control markers, including glycated hemoglobin (HbA1c), fasting glucose, and insulin resistance indices, also improved. One biopsy-based study demonstrated histological improvements, including reduced fibrosis and resolution of nonalcoholic steatohepatitis (NASH). No serious adverse events were reported. These findings suggest SGLT2 inhibitors may offer dual benefits for managing both diabetes and fatty liver disease. Further long-term studies focusing on liver histology as a primary endpoint are needed to confirm these effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.